What is the treatment of choice in a patient with atypical hemolytic uremic syndrome (aHUS)?

Eculizumab (plasma exchange within 24-48 hour of onset or admission if eculizumab is not immediately available). Eculizumab is a monoclonal C5 antibody that inhibits terminal complement complex formation.